Adaptimmune Therapeutics

Yahoo Finance • 12 months ago

Positive week for Adaptimmune Therapeutics plc (NASDAQ:ADAP) institutional investors who lost 68% over the past year

Key Insights Institutions' substantial holdings in Adaptimmune Therapeutics implies that they have significant influence over the company's share price A total of 8 investors have a majority stake in the company with 52% ownership Using d... Full story

Yahoo Finance • 2 years ago

Adaptimmune to Report Q1 2023 Financial and Business Updates on Friday, May 12, 2023

Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - April 28, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updat... Full story

Yahoo Finance • 2 years ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVT, PTRS, ROCC, ADAP

NEW YORK, April 13, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to sharehold... Full story

Yahoo Finance • 2 years ago

ALERT: The M&A Class Action Firm Continues Investigating the Merger – CNXC, INDT, HSKA, ADAP

NEW YORK, April 12, 2023 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Se... Full story

Yahoo Finance • 2 years ago

Why Shares of Adaptimmune Therapeutics Jumped Tuesday

Shares of Adaptimmune Therapeutics (NASDAQ: ADAP) were up as much as 9.7% early Tuesday after the clinical-stage biotech announced that it had reached an agreement with GSK (NYSE: GSK) to return the rights to Adaptimmune's PRAME and NY-ESO... Full story

Yahoo Finance • 2 years ago

STOCKHOLDER ALERT: The M&A Class Action Firm Continues its Investigation of the Merger – MLVF, SAL, ADAP, BRBW

NEW YORK, April 05, 2023 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Se... Full story

Yahoo Finance • 2 years ago

SHAREHOLDER ALERT: The M&A Class Action Firm Continues its Investigation of the Merger – ADAP, SAL, BRBW, MLVF

NEW YORK, March 29, 2023 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Se... Full story

Yahoo Finance • 2 years ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RADI, DSEY, ADAP, TCRR

NEW YORK, March 24, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to sharehold... Full story

Yahoo Finance • 2 years ago

ALERT: The M&A Class Action Firm Continues its Investigation of the Merger – MLVF, ADAP, BRBW, SAL

NEW YORK, March 22, 2023 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Se... Full story

Yahoo Finance • 2 years ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SGEN, ADAP, PRVB, XM

NEW YORK, March 19, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to sharehold... Full story

Yahoo Finance • 2 years ago

Lifshitz Law PLLC Announces Investigations of SGEN, PRVB, KBAL, and ADAP

NEW YORK, March 18, 2023 (GLOBE NEWSWIRE) -- Seagen Inc. (NASDAQ: SGEN) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of SGEN to Pfizer Inc. for $229.00 per share in c... Full story

Yahoo Finance • 2 years ago

ALERT: The M&A Class Action Firm Continues its Investigation of the Merger – ADAP, LBC, SAL, BRBW

NEW YORK, March 15, 2023 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS S... Full story

Yahoo Finance • 2 years ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates KBAL, DSEY, ADAP, TCRR

NEW YORK, March 09, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to sharehold... Full story

Yahoo Finance • 2 years ago

Lifshitz Law PLLC Announces Investigations of DSEY, KBAL, ADAP, and TCRR

NEW YORK, March 08, 2023 (GLOBE NEWSWIRE) -- Diversity Holdings, Ltd. (NASDAQ: DSEY) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of DSEY to Solenis for $8.40 per sha... Full story

Yahoo Finance • 2 years ago

STOCKHOLDER ALERT: The M&A Class Action Firm Continues its Investigation of the Merger – LBC, ADAP, BRBW, SAL

NEW YORK, March 08, 2023 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS S... Full story

Yahoo Finance • 2 years ago

Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors

Compelling clinical data with clear paths to products and multiple near‐term value-creating catalysts Complementary technology platforms designed to treat solid tumors which represents a substantial market opportunity largely unaddressed... Full story

Yahoo Finance • 2 years ago

Adaptimmune Enhances Its Pipeline of Wholly Owned Cell Therapies for Cancer with Transfer of PRAME and NY-ESO Target Programs from GSK

Adaptimmune gains full control of late-stage preclinical optimized PRAME TCR; IND-ready in 2023 – GSK to deliver data from the ongoing Phase 2 / potential registrational trial with lete-cel in sarcoma with final readouts expected in late 2... Full story

Yahoo Finance • 2 years ago

Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors

- 44% Objective Response Rate (ORR) with a single dose of ADP-A2M4CD8 in 25 heavily pre-treated patients with late-stage ovarian, urothelial, and head & neck cancers - - Further clinical development planned in ovarian (SURPASS-3), urothel... Full story

Yahoo Finance • 3 years ago

Preclinical Proof-of-Concept Data Supporting Future Clinical Development of Two New Cell Therapies Being Presented by Adaptimmune at ASGCT

- New next-gen SPEAR T-cells (ADP-A2M4N7X19) designed to enhance depth and durability of clinical response demonstrated enhanced proliferation, survival, and recruitment of immune cells in vitro - - Engineered TILs (ADP-TILIL7) intended t... Full story

Yahoo Finance • 3 years ago

Adaptimmune Reports First Quarter Financial Results and Business Update

- Pooled data from Cohort 1 of the SPEARHEAD-1 trial and the Phase 1 trial of afami-cel in patients with sarcoma to be presented as a poster at ASCO - - Preclinical data for two novel next-generation T-cell therapies to be presented in tw... Full story